Table 1.
Demographic, clinical, and immunological data in association with the ARV treatment regimens
| Parameters | ARV treatment regimens | |||
|
NRTI+NNRTI+PI (n = 15) |
NRTI+NNRTI (n = 6) |
NRTI + PI (n = 13) |
NRTIs (n = 7) |
|
| Age of study entry (Mean+/-SD, yrs) | 11.9+/-4.3 | 10.8+/-3.4 | 8.8+/-5.1 | 10.4+/-3.0 |
| Length of treatment (Mean+/-SD, yrs) | 7.8+/-3.1 | 6.7+/-2.3 | 5.1+/-2.8 | 5.8+/-2.7 |
| Number of Medications | ||||
| NRTI | 3.7+/-0.7 | 3.3+/-1.0 | 3.1+/-1.0 | 2.7+/-1.1 |
| NNRTI | 1.1 +/-0.2 | 1.2+/-0.4 | - | - |
| PI | 1.1+/-0.6 | - | 1.2+/-0.4 | - |
| Clinical categories * | ||||
| B | 8 (53.3%) | 3/5 (60.0%) | 4 (30.8%) | 3 (42.9%) |
| C | 7 (46.7%) | 2/5 (40.0%) | 9(69.2%) | 4 (57.1%) |
| Immune categories ** | ||||
| 1 (no suppression) | 10 (66.3%) | 4 (66.7%) | 7 (53.9%) | 3 (42.9%) |
| 2–3 (moderate/severe) | 7 (33.3%) | 2 (33.3%) | 6 (46.1%) | 4 (57.1%) |
| PVL (n, %) | ||||
| <10,000 | 5 (33.3%) | 4 (66.7%) | 2 (15.4%) | 4 (57.1%) |
| ≥ 10,000 | 10 (66.7%) | 2 (33.3%) | 11 (84.6%) | 3 (42.9%) |
| Number of mutations (Mean+/-SD) | 5.7+/-3.8 | 3.5+/-1.6 | 4.7+/-3.2 | 3.7+/-2.3 |
*B-moderately, C-severely symptomatic 22,23
** Immune categories based on age-specific CD4+ T-lymphocyte count.22,23